Oblenio Bio
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4 Maguire Rd, Lexington, Massachusetts, ...Website
www.obleniobio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Oblenio Bio
Oblenio Bio is a biotechnology company developing next-generation immunotherapies for severe autoimmune diseases. The company is advancing tri-specific T-cell engager therapies designed to selectively deplete disease-causing immune cells and achieve long-term immune reset. Its research focuses on addressing the underlying mechanisms of autoimmune disorders to develop transformative treatments with the potential for durable, drug-free remission.Explore more
Oblenio Bio Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oblenio Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Oblenio Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Oblenio Bio launches new products
Click to see if Oblenio Bio had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Oblenio Bio recently announced quarterly report
Check out if Oblenio Bio is spiking on competitors!
Funding: Get notified immidiatlly once Oblenio Bio has new funding data
Check if Oblenio Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Oblenio Bio
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Oblenio Bio financials insights
Gather financial insights about Oblenio Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series B
$62M
Oblenio Bio News & Media
Oblenio Bio closes $62 million Series B led by Pfizer Ventures | The Pharmaletter
Cambridge, USA-based Oblenio Bio has announced the closing of an oversubscribed $62 million Series B financing round, positioning the company as an emerging leader in the treatment of autoimmune disease.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Oblenio Bio
Sign Up For FreeTo access detailed company insights
Oblenio Bio is a biotechnology company developing next-generation immunotherapies for severe autoimmune diseases. The company is advancing tri-specific T-cell engager therapies designed to selectively deplete disease-causing immune cells and achieve long-term immune reset. Its research focuses on addressing the underlying mechanisms of autoimmune d... Read More
